Synergism between factor XII -4C>T and factor XIII Val34Leu polymorphisms in fibrinolytic therapy in acute myocardial infarction

Thrombosis and Haemostasis

Volumn 104, Issue 3, 2010, Pages 650-652

  Hernández Romero, Diana ^a   Marín, Francisco ^a   Lee, Kaeng W ^b   Roldán, Vanessa ^a   Caturla, Juan ^c   Corral, Javier ^a   Valdés, Mariano ^a   Lip, Gregory Y H ^b   Vicente, Vicente ^a   González Conejero, Rocío ^a  

^a UNIVERSITY OF MURCIA   (Spain)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; BLOOD CLOTTING FACTOR 12; BLOOD CLOTTING FACTOR 13; STREPTOKINASE; TENECTEPLASE;

ACUTE HEART INFARCTION; BLOOD CLOT LYSIS; DISEASE ASSOCIATION; FIBRINOLYTIC THERAPY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; LETTER; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; ST SEGMENT ELEVATION; THERAPY DELAY;

AGED; CHI-SQUARE DISTRIBUTION; FACTOR XII; FACTOR XIII; FEMALE; GENOTYPE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; ODDS RATIO; PHENOTYPE; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SPAIN; THROMBOLYTIC THERAPY; TREATMENT OUTCOME;

EID: 77956636062     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH10-01-0022     Document Type: Letter

References (22)

1. Zeerleder S, Schloesser M, Redondo M, et al. Reevaluation of the incidence of thromboembolic complications in congenital factor XII deficiency -a study on 73 subjects from 14 Swiss families. Thromb Haemost 1999; 82: 1240-1246. (Pubitemid 29473785)
2. Kanaji T, Okamura T, Osaki K, et al. A common genetic polymorphism (46 C to T substitution) in the 5′-untranslated region of the coagulation factor XII gene is associated with low translation efficiency and decrease in plasma factor XII level. Blood 1998; 91: 2010-2014.
3. Millar GJ, Esnouf MP, Burgués AI, et al. Risk of coronary Heart disease and activation of factor XII in middle-aged men. Arterioscl Thromb Vac Biol 1997; 17: 2103-2106. (Pubitemid 28057114)
4. Zito F, Drummond F, Bujac S, et al. Epidemiological and genetic association of activated factor XII concentration with factor VII activity, fibrinopeptide A concentration, and risk of coronary heart disease in men. Circulation 2000; 102: 2058-2062.
5. Kohler HP, Futres TS, Grant PJ. FXII (46C->T) polymorphism and in vivo generation of FXII activity-gene frequencies and relationship in patients with coronary artery disease. Thromb Haemost 1999; 81: 745-747.
6. Zito F, Lowe GD, Rumley A, et al. WOSCOPS Study. Association of the factor XII 46 C->T polymorphism with risk of coronary heart disease in the WOSCOPS study. Atherosclerosis 2002; 165: 153-158.
7. Santamaría A, Mateo J, Tirado I, et al. Homozygosity of the T allele of the 46 C->T polymorphism in the F12 gene is a risk factor for ischemic stroke in spanish population. Stroke 2004; 35: 1795-1799. (Pubitemid 38971853)
8. Kleinschnitz C, Stoll G, Bendszus M, et al. Targeting coagulation factor XII provides protection form pathological thombosis in cerebral ischemia without interfering with hemostasis. J Exp Med 2006; 203; 513-518.
9. Müller F, Renné T. Novel roles for factor XII-driven plasma contact activation system. Curr Opin Hematol 2008; 15: 516-521.
10. Armstrong PW, Collen D. Fibrinolityc for acute myocardial infarction: current status and new horizons for pharmacological reperfusion, part 1. Circulation 2001; 103: 2862-2866. (Pubitemid 32550078)
11. Rallidis LS, Politou M, Komporozos C, et al. Factor XIII Val34Leu polymorphism and the risk of myocardial infarction under the age of 36 years. Thromb Haemost 2008; 99: 1085-1089.
12. Marín F, González-Conejero R, Lee KW, et al. A pharmacogenetic effect of factor XIII valine 34 Leucine polymorphism on fibrinolytic therapy for acute myocardial infarction. J Am Coll Cardiol 2005; 45: 25-29.
13. González-Conejero R, Fernández-Cadenas I, Iniesta JA, et al. for the Proyecto Ictus Research Group. Role of fibrinogen levels and factor XIII V34L polymorphism in thombolytic therapy in stroke patients. Stroke 2006; 37: 2288-2293.
14. Rader DJ, Puré E. Genetic Susceptibility to Atherosclerosis: Insights From Mice. Circ Res 2000; 86: 1013-1015.
15. Bergmann SR, Sobel BE. Noninvasive assessment of the efficacy of coronary thrombolysis. In: Thrombolysis in Cardiovascular Disease. New York, NY: Marcel Dekker, 1989: pp. 141-161.
16. Corral J, González-Conejero R, Iniesta JA, et al. The FXIII Val34Leu polymorphism in venous and arterial thromboembolism. Haematologica 2000; 85: 293-297. (Pubitemid 30340147)
17. Ariëns RAS, Philippou H, Nagaswami C, et al. The factor XIII V34L polymorphism accelerates thrombin activation of factor XIII and affects cross-linked fibrin structure. Blood 2000; 96: 988-995.
18. Cannon CP. Importance of TIMI 3 flow. Circulation 2001; 104: 624-627.
19. Gibson CM, Cannon CP, Murphy SA, et al., for the TIMI 10B Investigators. Relationship of TIMI myocardial perfusion grade to mortality following thrombolytic administration. Circulation 2000; 101: 125-130.
20. Syed MA, Borzak S, Asfour A, et al. Single lead ST-segment recovery: a simple, reliable measure of successful fibrinolysis after acute myocardial infarction. Am Heart J 2004; 147: 275-280.
21. Puleo PR, Perryman MB, Bresser MA, et al. Creatine kinase isoform analysis in the detection and assessment of thrombolysis in man. Circulation 1987; 75: 1162-1169.
22. Marín F, González-Conejero R, Capranzano P, et al. Pharmacogenetics in cardiovascular antithrombotic therapy. J Am Coll Cardiol 2009; 54: 1041-1057.